Guangzhou Anhao Pharmaceutical Technology Co., Ltd.

1. Primary purpose: To evaluate the effectiveness of DX1002 in Chinese patients with advanced hepatocellular carcinoma/gastric cancer, and provide reference for the next clinical study. 2. Secondary purpose: To further evaluate the pharmacokinetic/pharmacodynamic characteristics of DX1002 in Chinese patients with advanced hepatocellular carcinoma/gastric cancer after administration. To evaluate the changes in the quality of life of the subjects before and after administration. To further evaluate the safety and tolerability of DX1002 in Chinese patients with advanced hepatocellular carcinoma/gastric cancer after administration. 3. Exploratory purpose: (Exploratory stage only) To observe the internal necrosis of the tumor target lesions before and after administration. To observe the changes in the blood supply of the tumor target lesions before and after administration.

1) Evaluate the safety and tolerability of DX1002 tablets; 2) Determine the maximum tolerated dose and/or Phase II recommended dose of DX1002 tablets; 3) Observe the pharmacokinetic characteristics of DX1002 tablets. 4) Preliminary evaluation of the anti-tumor efficacy of DX1002 tablets; 5) Explore the correlation between the blood flow changes caused by DX1002 tablets and PK and efficacy.